Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202149 | 0.92 | EGFR (0.64) | EGFRKCNH2IGF1R | |
| SCHEMBL18239603 | 0.91 | EGFR (0.74) | EGFRKCNH2IGF1R | |
| SCHEMBL18239597 | 0.89 | EGFR (0.63) | EGFRKCNH2IGF1R | |
| SCHEMBL18239602 | 0.87 | EGFR (0.48) | EGFRKCNH2IGF1R | |
| SCHEMBL18202334 | 0.87 | EGFR (0.73) | EGFRKCNH2 | |
| SCHEMBL18202150 | 0.86 | EGFR (0.56) | EGFRKCNH2IGF1R | |
| SCHEMBL18229905 | 0.86 | EGFR (0.84) | EGFRKCNH2IGF1R | |
| SCHEMBL19921310 | 0.85 | EGFR (0.59) | EGFRKCNH2IGF1R | |
| SCHEMBL18202241 | 0.85 | EGFR (0.55) | EGFR | |
| SCHEMBL18202246 | 0.84 | EGFR (0.57) | EGFRKCNH2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2016183278-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323976-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ERBB2, EGFR, ERBB3 | EGFR 2/4885KCNH2 4480/4885IGF1R 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.